舒格利单抗辅助同步放化疗对晚期肺癌患者肿瘤控制及预后的影响  

Effect of Concurrent Chemoradiotherapy Combined with Sugemalimab on Tumour Response and Prognosis of Patients with Advanced Lung Cancer

作　　者：梁辉 曾炜琦 赵飞 Liang Hui;Zeng Wei-qi;Zhao Fei(Department of Radiotherapy,The First Affiliated Hospital of Henan University of Science and Technology,Luoyang 471000,Henan,China)

机构地区：[1]河南科技大学第一附属医院放疗科,河南洛阳471000

出　　处：《四川生理科学杂志》2024年第7期1484-1487,共4页

摘　　要：目的:探究同步放化疗联合舒格利单抗对晚期肺癌患者肿瘤控制及预后的影响。方法:选取2022年1月至2023年1月于我院进行就诊的82例晚期肺癌肿瘤患者为研究对象,根据随机抽签法,分为对照组和实验组,各41例。对照组给予常规同步放化疗治疗(顺铂+依托泊苷)方案,实验组给予舒格利单抗辅助同步放化疗治疗方案。治疗6 w后使用实体瘤疗效评定标准和功能状态评分观察两组患者治疗后的短期疗效,使用流式细胞术观察T淋巴细胞亚群水平,采用Log Rank χ^(2)检验比较两组患者的半年生存率。结果:治疗6 w后,实验组的客观缓解率为65.85%,明显高于对照组的29.26%(P<0.05)。而实验组的疾病控制率为92.86%,较对照组的75.60%略高(P>0.05)。治疗结束后,实验组患者的生存质量稳定改善率为87.81%,高于对照组的41.46%(P<0.05)。治疗后,实验组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)高于对照组(P<0.05);实验组CD8^(+)水平低于对照组(P<0.05)。随访6 m内,对照组患者病死率14.63%,实验组病死率4.88%,两组患者预后病死率差异有统计学意义(χ^(2)=4.203,P=0.040)。结论:同步放化疗联合舒格利单抗可提高晚期非小细胞肺癌的近期疗效及预后,改善患者免疫状态,提高生存质量,具有较好的临床应用价值。Objective:To investigate the effect of simultaneous radiotherapy and chemotherapy combined with sugolizumab on tumor control and prognosis of advanced lung cancer patients.Methods:Eighty-two patients with advanced lung cancer who attended our hospital from January 2022 to January 2023 were selected as the study subjects,and were divided into the control group and the experimental group,41 cases each,according to the random draw method.The control group was given conventional synchronous radiotherapy treatment(cisplatin+etoposide)regimen,and the experimental group was given suglizumab-assisted synchronous radiotherapy treatment regimen.After 6 weeks of treatment,the short-term efficacy of the two groups was observed using the solid tumor efficacy evaluation criteria and the functional status score,and the level of T-lymphocyte subpopulations was observed using flow cytometry,and the six-month survival rate of the two groups was compared using the Log Rank χ^(2) test.Results:After six weeks of treatment,the objective remission rate of the experimental group was 65.85%,which was significantly higher than that of the control group,which was 29.26%(P<0.05).And the disease control rate of the experimental group was 92.86%,which was slightly higher than the 75.60%of the control group(P>0.05).At the end of treatment,the rate of stable improvement in the quality of survival of patients in the experimental group was 87.81%,which was higher than that of 41.46%in the control group(P<0.05).After treatment,CD3^(+),CD4^(+),and CD4^(+)/CD8^(+)were higher in the experimental group than in the control group(P<0.05);CD8^(+)levels were lower in the experimental group than in the control group(P<0.05).Within 6 months of follow-up,the disease and death rate of patients in the control group was 14.63%,and the disease and death rate of the experimental group was 4.88%,and the difference in the prognostic disease and death rate of patients in the two groups was statistically significant(χ^(2)=4.203,P=0.040).Conclusion:Synchronous radio

关 键 词：同步放化疗 舒格利单抗 非小细胞肺癌 肿瘤控制 

分 类 号：R734.2[医药卫生—肿瘤]